Zirconium 89Zr crefmirlimab berdoxam

Phase 2Biologic

IImaginAb, Inc.

Zirconium 89Zr crefmirlimab berdoxam is one of 68 biologic programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerRecruiting

MalignanciesActive, not recruiting

Lung CancerPhase 1

Recruiting

MalignanciesPhase 2

Active, not recruiting

Competition

Competitive Landscape

206 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Tagrisso

AstraZeneca

Phase 3

19 2

Beyfortus

BeiGene

Phase 3

10 3

Abraxane

Bristol-Myers Squibb

Phase 3

7 4

Alecensa

Roche

Phase 3

3 5

DATROWAY

Daiichi Sankyo

Phase 3

2 6

Ilaris

Novartis

Phase 3

2 7

Verzenio

Eli Lilly

Phase 3

2 8

Lynparza

AstraZeneca

Phase 3

2 9

Zepzelca

Jazz Pharmaceuticals

Phase 3

2 10

Tarlatamab-Dznl

Amgen

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Lung Cancer

NCT06863233

Clinical

Trials by Indication[1]

Malignancies1 trial

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

Active, not recruiting·IImaginAb, Inc.·Phase 2·NCT05013099·70 enrolled

Lung Cancer1 trial

Assessment of Patients Immune Response After Treatment With Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT06863233·5 enrolled

Unspecified1 trial

CD8 Minibody Repeatability Study

Terminated·IImaginAb, Inc.·Phase 2·NCT05744128·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Zirconium 89Zr crefmirlimab berdoxam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zirconium 89Zr crefmirlimab berdoxam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zirconium 89Zr crefmirlimab berdoxam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImaginAb, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: IImaginAb, Inc.

Zirconium 89Zr crefmirlimab berdoxam

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Malignancies1 trial

Lung Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News